Follow-up of Gynecological Cancer Patients, Their Needs and Expectations, A Cooperation Project
- Status
- COMPLETED
- Phase
- N/A
Clinical Trials Related to Ovarian Cancer
Related studies linked through entity extraction aliases.
Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
PTX-200 and Carboplatin in Ovarian Cancer
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Safety and Biodistribution of Technetium Tc 99m EC20 in Normal Volunteers and Ovarian Cancer Patients
- Status
- COMPLETED
- Phase
- PHASE1
Safety and Efficacy of FolateScan (Technetium Tc 99m EC20) in Women With Suspected Ovarian or Endometrial Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy
- Status
- TERMINATED
- Phase
- PHASE2
Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)
- Status
- COMPLETED
- Phase
- PHASE3
Efficacy Study of FloSeal for Prevention of Lymphocele After Lymphadenectomy for Gynecologic Cancer
- Status
- COMPLETED
- Phase
- NA
Availability & Effect of Post-OP Ketorolac on Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Olaparib for Patients With Recurrent BRCA Deficient Ovarian Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
ICON8: Weekly Chemotherapy in Ovarian Cancer
- Status
- UNKNOWN
- Phase
- PHASE3
CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE2
BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE1
An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Influence of Chemotherapy on Gamma-delta T Cells in Patients With Epithelial Ovarian Cancer
- Status
- WITHDRAWN
- Phase
- N/A